NO873091L - Fremgangsmaate for fremstilling av nye benzimidazolderivater. - Google Patents

Fremgangsmaate for fremstilling av nye benzimidazolderivater.

Info

Publication number
NO873091L
NO873091L NO873091A NO873091A NO873091L NO 873091 L NO873091 L NO 873091L NO 873091 A NO873091 A NO 873091A NO 873091 A NO873091 A NO 873091A NO 873091 L NO873091 L NO 873091L
Authority
NO
Norway
Prior art keywords
procedure
preparation
new
benzimidazold
derivatives
Prior art date
Application number
NO873091A
Other languages
English (en)
Other versions
NO168770B (no
NO873091D0 (no
NO168770C (no
Inventor
Noriyoshi Sueda
Yoshikuni Suzuki
Toshiji Sugai
Hiroaki Yamada
Makoto Yanai
Original Assignee
Nisshin Flour Milling Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Flour Milling Co filed Critical Nisshin Flour Milling Co
Publication of NO873091D0 publication Critical patent/NO873091D0/no
Publication of NO873091L publication Critical patent/NO873091L/no
Publication of NO168770B publication Critical patent/NO168770B/no
Publication of NO168770C publication Critical patent/NO168770C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO873091A 1986-07-25 1987-07-23 Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater NO168770C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17375986 1986-07-25
JP62171139A JPH0784462B2 (ja) 1986-07-25 1987-07-10 ベンゾイミダゾ−ル誘導体

Publications (4)

Publication Number Publication Date
NO873091D0 NO873091D0 (no) 1987-07-23
NO873091L true NO873091L (no) 1988-01-26
NO168770B NO168770B (no) 1991-12-23
NO168770C NO168770C (no) 1992-04-01

Family

ID=26493951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO873091A NO168770C (no) 1986-07-25 1987-07-23 Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater

Country Status (10)

Country Link
US (1) US4886803A (no)
EP (1) EP0254322B1 (no)
JP (1) JPH0784462B2 (no)
KR (1) KR960011388B1 (no)
AU (1) AU597696B2 (no)
CA (1) CA1305481C (no)
DE (1) DE3781845T2 (no)
ES (1) ES2044878T3 (no)
FI (1) FI91152C (no)
NO (1) NO168770C (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58907869D1 (de) * 1988-03-21 1994-07-21 Ciba Geigy Mittel zum Schutz von Pflanzen gegen Krankheiten.
US5089592A (en) * 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
EP0602586B1 (en) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
US5637725A (en) * 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
US5637724A (en) * 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
TW381092B (en) * 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
WO2001058879A1 (en) * 2000-02-09 2001-08-16 The Procter & Gamble Company 2-phenylcarbamoyl-benzimidazoles
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
FR2833494B1 (fr) * 2001-12-19 2006-12-15 Univ Nantes Utilisation de composes de la famille des benzamides comme agent immunosuppresseur
JP2005289816A (ja) * 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
AU2003284165B2 (en) * 2002-10-30 2008-12-11 Merck Sharp & Dohme Corp. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
AU2006296004B2 (en) 2005-09-27 2011-11-17 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0712039A2 (pt) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2054041A2 (en) * 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
IL197129A (en) * 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for production
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2771568A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Heteroaryl compounds as kinase inhibitors
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634704A (en) * 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines

Also Published As

Publication number Publication date
DE3781845D1 (de) 1992-10-29
JPS63146871A (ja) 1988-06-18
NO168770B (no) 1991-12-23
EP0254322A1 (en) 1988-01-27
FI873205A0 (fi) 1987-07-21
DE3781845T2 (de) 1993-02-18
EP0254322B1 (en) 1992-09-23
FI91152B (fi) 1994-02-15
ES2044878T3 (es) 1994-01-16
JPH0784462B2 (ja) 1995-09-13
US4886803A (en) 1989-12-12
KR960011388B1 (ko) 1996-08-22
NO873091D0 (no) 1987-07-23
FI91152C (fi) 1994-05-25
AU597696B2 (en) 1990-06-07
CA1305481C (en) 1992-07-21
NO168770C (no) 1992-04-01
FI873205A7 (fi) 1988-01-26
AU7596587A (en) 1988-01-28
KR880001611A (ko) 1988-04-25

Similar Documents

Publication Publication Date Title
NO873091D0 (no) Fremgangsmaate for fremstilling av nye benzimidazolderivater.
NO871727D0 (no) Fremgangsmaate for fremstilling av nye kinolinderivater.
NO870579D0 (no) Fremgangsmaate for fremstilling av indolizin-derivater.
NO874904D0 (no) Fremgangsmaate for fremstilling av nye imidazopyridin-forbindelser.
NO862661D0 (no) Fremgangsmaate for fremstilling av n-aralkylpiperidinmethanolderivater.
NO852565L (no) Fremgangsmaate for fremstilling av nye funksjonelle gangliosid-derivater.
NO880452D0 (no) Fremgangsmaate for fremstilling av nye polyaminderivater.
NO865013D0 (no) Fremgangsmaate for fremstilling av antibaktercelle kinolon-derivater.
NO904059D0 (no) Fremgangsmaate for fremstilling av nye substituerte isokinoliner.
NO864108D0 (no) Fremgangsmaate for fremstilling av nye flavon-derivater.
NO163453C (no) Fremgangsmaate for fremstilling av sphingosinderivater.
NO901813L (no) Fremgangsmaate for fremstilling av nye tieno-triazolo-diazepin-derivater.
NO892543L (no) Fremgangsmaate for fremstilling av nye neplanocinderivater.
NO860429L (no) Fremgangsmaate for fremstilling av imidazolyl-indol-derivater.
NO892977L (no) Fremgangsmaate for fremstilling av nye s-adenosylmethionin-derivater.
NO854577L (no) Fremgangsmaate for fremstilling av nye tienopyridinderivater.
NO872393L (no) Fremgangsmaate for fremstilling av nye aralkylimidazolderivater.
NO891381D0 (no) Fremgangsmaate for fremstilling av nye fluorfosfonatnukleotidderivater.
NO904069D0 (no) Fremgangsmaate for fremstilling av nye alkanofenoner.
NO874199D0 (no) Fremgangsmaate for fremstilling av imidazo-pyridinonderivater.
NO871721L (no) Fremgangsmaate for fremstilling av nye ergolenderivater.
NO822185L (no) Fremgangsmaate for fremstilling av nye derivater av benzoylfenylpiperidin.
NO874698L (no) Fremgangsmaate for fremstilling av 2-guanidinothiazolderivater.
NO873019D0 (no) Fremgangsmaate for fremstilling av tetrahydrobenzotiazolkinolin-derivater.
NO862493D0 (no) Fremgangsmaate for fremstilling av 2-halonicergolinderivater.